Suppr超能文献

立体定向体部放疗或手术切除治疗转移性肉瘤的局部控制效果。

Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma.

机构信息

Medical College of Wisconsin, Wauwatosa, Wisconsin.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.

出版信息

Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):771-779. doi: 10.1016/j.ijrobp.2022.05.017. Epub 2022 May 26.

Abstract

PURPOSE

Traditional management of metastatic sarcoma primarily relies on systemic therapy, with surgery often used for tumor control. We analyzed the rates of recurrence, overall survival, and treatment complications in patients undergoing either surgical resection or stereotactic body radiation therapy (SBRT) for metastatic sarcoma of the bone and/or soft tissue.

METHODS AND MATERIALS

The records of patients with metastatic sarcoma between 2009 and 2020 were reviewed. Local recurrence (LR) was defined as tumor growth or recurrence at the tumor site. Cumulative LR incidence was analyzed accounting for the competing risk of death, and groups were compared using the Gray test. Overall survival (OS) was assessed using the Kaplan-Meier method and log-rank test. Hazard ratios were determined using the Cox proportional hazards model.

RESULTS

A total of 525 metastatic lesions in 217 patients were analyzed. The mean age of patients was 57 years (range, 4-88 years). The lung was the predominant site treated (50%), followed by intra-abdominal (13%) and soft tissue (11%). Two-year cumulative incidences of LR for surgery and SBRT were 14.8% (95% confidence interval [CI], 11.6%-18.5%) and 1.7% (95% CI, 0.1%-8.2%), respectively (P = .003). Local recurrence occurred in 72 (16.5%) of 437 tumors treated with surgery and 2 (2.3%) of 88 tumors treated with SBRT. The adjusted hazard ratio for LR of lesions treated surgically was 11.5 (P = .026) when controlling for tumor size and tumor site. Median OS was 29.8 months (95% CI, 25.6-40.9 months). There were 47 surgical complications among a total of 275 procedures (18%). Of 58 radiation treatment courses, radiation-related toxic effects were reported during the treatment of 7 lesions (12%), and none were higher than grade 2.

CONCLUSIONS

We observed excellent local control among patients selected for treatment with SBRT for metastatic sarcoma, with no evidence of an increase in LR after SBRT compared with surgical management. Further investigation is necessary to better define the most appropriate local control strategies for metastatic sarcoma.

摘要

目的

转移性肉瘤的传统治疗主要依赖于全身治疗,手术通常用于肿瘤控制。我们分析了接受骨和/或软组织转移性肉瘤切除术或立体定向体部放射治疗(SBRT)的患者的复发率、总生存率和治疗并发症。

方法和材料

回顾了 2009 年至 2020 年间患有转移性肉瘤的患者的记录。局部复发(LR)定义为肿瘤部位的肿瘤生长或复发。考虑到死亡的竞争风险,分析累积 LR 发生率,并使用 Gray 检验比较组。使用 Kaplan-Meier 方法和对数秩检验评估总生存率(OS)。使用 Cox 比例风险模型确定危险比。

结果

共分析了 217 例患者的 525 个转移性病变。患者的平均年龄为 57 岁(范围,4-88 岁)。肺部是治疗的主要部位(50%),其次是腹腔内(13%)和软组织(11%)。手术和 SBRT 的 2 年累积 LR 发生率分别为 14.8%(95%CI,11.6%-18.5%)和 1.7%(95%CI,0.1%-8.2%)(P=0.003)。接受手术治疗的 437 个肿瘤中有 72 个(16.5%)和接受 SBRT 治疗的 88 个肿瘤中有 2 个(2.3%)发生局部复发。控制肿瘤大小和肿瘤部位后,手术治疗的 LR 调整后的危险比为 11.5(P=0.026)。中位 OS 为 29.8 个月(95%CI,25.6-40.9 个月)。在总共 275 例手术中有 47 例发生手术并发症。在 58 例放射治疗中,有 7 例(12%)在治疗过程中报告了与放射相关的毒性反应,且均未高于 2 级。

结论

我们观察到接受 SBRT 治疗的转移性肉瘤患者的局部控制效果非常好,与手术治疗相比,SBRT 后没有证据表明 LR 增加。需要进一步研究以更好地确定转移性肉瘤的最佳局部控制策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验